Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CCR4 | P51679 | 7/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299559 | 1.00 | TP53 (0.44) | TP53CCR4HSD11B1PIK3CDLMNA | |
| SCHEMBL3293681 | 0.95 | TP53 (0.46) | TP53CCR4HSD11B1LMNATHRB | |
| SCHEMBL3294842 | 0.95 | TP53 (0.46) | TP53CCR4HSD11B1LMNATHRB | |
| SCHEMBL3291439 | 0.93 | TP53 (0.48) | TP53CCR4HSD11B1LMNATHRB | |
| SCHEMBL3293130 | 0.89 | TP53 (0.48) | TP53CCR4HSD11B1PIK3CDSCN9A | |
| SCHEMBL3291273 | 0.89 | TP53 (0.44) | TP53CCR4HSD11B1PIK3CDLMNA | |
| SCHEMBL3293365 | 0.88 | TP53 (0.46) | TP53CCR4HSD11B1LMNATHRB | |
| SCHEMBL3298329 | 0.88 | TP53 (0.45) | TP53CCR4HSD11B1PIK3CDLMNA | |
| SCHEMBL3293120 | 0.88 | TP53 (0.49) | TP53CCR4LMNATHRBSCN9A | |
| SCHEMBL3298225 | 0.86 | TP53 (0.45) | TP53CCR4HSD11B1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | CCR5, CCR4, CCR1 | TP53 2581/4885CCR4 2/4885HSD11B1 308/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | TP53 2581/4885CCR4 2/4885HSD11B1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.